The application follows guidance provided to IMUNON (IMNN) in Pre-IND meeting with the FDA LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage ...
Immuneering Corporation IMRX announced that it has submitted an investigational new drug (IND) application to the FDA to begin a clinical study on its lead product candidate IMM-1-104 for the ...
UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results